Related Experiment Video
Updated: Aug 24, 2026

Methods to Study Mrp4-containing Macromolecular Complexes in the Regulation of Fibroblast Migration
Published on: May 19, 2016
Activation of MAP kinase by MC4-R through PI3 kinase
Aurawan Vongs1, Nicole M Lynn, Charles I Rosenblum
1Department of Metabolic Research-Obesity, Merck Research Laboratories, Merck and Co., P.O. Box 2000, RY80M-213 Rahway, NJ 07065, USA.
Abstract:
The melanocortin 4 receptor (MC4-R) is a Galpha s-coupled receptor known to increase cAMP production following agonist stimulation. We demonstrate that the mitogen-activated protein kinases p42 (ERK2) and p44 (ERK1) are also activated by MC4-R following treatment with the MC4-R agonist NDP-alpha-MSH in stably transfected CHO-K1 cells. This time- and dose-dependent response is abolished by the MC4-R antagonist SHU-9119. p42/p44 MAPK activation is blocked by the phosphatidylinositol 3-kinase (PI3K) inhibitors wortmannin and LY294002 but not by the protein kinase A (PKA) inhibitor Rp-cAMPS, indicating that that signal activating the p42/p44 MAPK pathway is conveyed through inositol triphosphate.
Insights
Melanocortin 4 receptor (MC4-R) activation triggers both cAMP and MAPK pathways. This study reveals MC4-R signaling involves phosphatidylinositol 3-kinase (PI3K) in activating p42/p44 MAPK.
Area of Science:
- Cellular signaling pathways
- Receptor pharmacology
- Molecular biology
Background:
- The melanocortin 4 receptor (MC4-R) is a G protein-coupled receptor primarily involved in regulating energy homeostasis.
- MC4-R is known to activate adenylyl cyclase, leading to increased cyclic AMP (cAMP) production upon agonist binding.
Purpose of the Study:
- To investigate the downstream signaling pathways activated by the melanocortin 4 receptor (MC4-R) beyond cAMP production.
- To determine if mitogen-activated protein kinases (MAPKs) are activated by MC4-R stimulation and to elucidate the signaling cascade involved.
Main Methods:
- Utilized stably transfected CHO-K1 cells expressing MC4-R.
- Stimulated cells with the MC4-R agonist NDP-alpha-MSH and observed responses.
- Employed MC4-R antagonist SHU-9119 to confirm receptor specificity.
- Used phosphatidylinositol 3-kinase (PI3K) inhibitors (wortmannin, LY294002) and a protein kinase A (PKA) inhibitor (Rp-cAMPS) to dissect the signaling pathway.
Main Results:
- MC4-R activation by NDP-alpha-MSH led to the activation of p42 (ERK2) and p44 (ERK1) MAPKs in a time- and dose-dependent manner.
- This MAPK activation was specifically blocked by the MC4-R antagonist SHU-9119.
- Inhibition of PI3K with wortmannin or LY294002 abolished p42/p44 MAPK activation.
- Conversely, the PKA inhibitor Rp-cAMPS did not affect MC4-R-mediated MAPK activation.
Conclusions:
- MC4-R signaling extends to the activation of the p42/p44 MAPK pathway.
- The activation of the MAPK pathway by MC4-R is dependent on phosphatidylinositol 3-kinase (PI3K) activity.
- The findings suggest that inositol triphosphate mediates the signal transduction from MC4-R to the MAPK pathway, independent of PKA/cAMP.
Related Concept Videos
MAPK Signaling Cascades
PI3K/mTOR/AKT Signaling Pathway
Calmodulin-dependent Signaling
The Ca2+-CaM complex does not have enzymatic activity by itself. Instead, the complex binds downstream target proteins, including membrane proteins or enzymes,...
The JAK-STAT Signaling Pathway
IP3/DAG Signaling Pathway
Microtubule Associated Proteins (MAPs)

